Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) issued the following statement regarding the Biden administrations plans to use so-called “march-in rights” on pharmaceutical patents:

“Patients battling cancer or other rare diseases will be among those harmed most by the Biden administration’s unprecedented action that doubles down on the IRA’s innovation-killing drug price setting regime. It will destroy the types of public-private partnerships—including at NIH’s newly formed ARPA-H—that are critical for conducting research on rare conditions that affect smaller patient populations. By bowing to the most radical voices in his political party, the President is again undercutting any chance he might have had at achieving his Cancer Moonshot goals. He should abandon this plan immediately and stop taking hope for treatments and cures away from the patients most in need.”